According to a 2024 article by the Columbia University Department of Psychiatry, semaglutides 2021 FDA approval came with wide recognition for its medical benefits and its notable side effect of weight loss. What resulted from that was a surge in its off-label use as a weight-loss aid, propelling the drug into the spotlight far beyond its original intent. Then, also in 2021, the FDA approved Wegovy for individuals who are obese or overweight with additional health challenges. Columbia University also notes the ethical concerns of drugs like Ozempic and Wegovy, particularly in their pricing
Certain medical conditions and other factors may increase the risk of interactions with levothyroxine
Ubiquinol, the reduced form of CoQ10, is often marketed as more bioavailable than ubiquinone, particularly in older adults or those with absorption issues, though both forms appear effective
This has led to a large interest in the development of weight-loss drugs that may not have as much of an effect on skeletal muscle mass as semaglutide does
Decentralized Clinical Trials (DCTs) The hybrid trial model has become the standard
Mallick R, Basak S, Das RK, Banerjee A, Paul S, Pathak S, et al
